Jul 28,2022

Dexcom to update next-gen G7 software, delaying FDA clearance, launch timelines

The CEO of Dexcom (Nasdaq:DXCM) said today that the company’s regulatory path for the next-generation G7 has been slightly delayed.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 01,2022

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Omnipod® 5 Automated Insulin Delivery (AID) System (Omnipod 5) is now fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 03,2022

Diabetes Reversal Leader Virta Health Receives Recognition for Delivering Best-In-Class Cost Savings and Health Outcomes

Virta Health, the leader in type 2 diabetes reversal, is the first digital health solution to receive Validation Institute’s newly-developed Program Validation. With this validation, Virta is recognized for the rigorous, evidence-based research underlying its diabetes reversal treatment, as well as its best-in-class financial and health outcomes for employer customers.

View Analyst & Ambassador Comments
Go to original news
Aug 03,2022

Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem

Senseonics Holdings, Inc. a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Anthem is providing coverage for implantable CGM, which includes the Eversense® CGM System. Anthem’s decision will add more than 45 million covered lives for the long-term implantable CGM system to help manage their diabetes.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 04,2022

BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS

BD, a leading global medical technology company, today announced results for its third quarter of fiscal year 2022, which ended June 30, 2022.

View Analyst & Ambassador Comments
Go to original news
Aug 04,2022

Detection of Hypoglycemia and Hyperglycemia Using Noninvasive Wearable Sensors: ECG and Accelerometry

Monitoring glucose excursions is important in diabetes management. This can be achieved using continuous glucose monitors (CGMs). However, CGMs are expensive and invasive. Thus, alternative low-cost noninvasive wearable sensors capable of predicting glycemic excursions could be a game changer to manage diabetes.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Aug 04,2022

Abbott, WeightWatchers partner on diabetes care

The two companies will work together to allow Abbott's FreeStyle Libre continuous glucose monitoring systems and the WeightWatchers mobile app to share information so that people living with diabetes can see their glucose data alongside WeightWatchers' diabetes-tailored program.  

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 05,2022

Insulet to Present at Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at four upcoming investor conferences (all Eastern Time): The Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 4:30 p.m. The 2022 Wells Fargo Healthcare conference on Friday, September 9, 2022, at 8:00 a.m. The Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 3:30 p.m. The Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 12:15 p.m.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Aug 05,2022

Novel Methods to Understand the Temporal Nature and Accuracy of Delivery for Insulin Infusion Pumps

A wide suite of methods are available to evaluate delivery accuracy of insulin pumps. However, these methods do not capture any temporal information, which may be critical for design of artificial pancreas (AP) systems. We propose a novel video microscopy method to understand the delivery accuracy and temporal nature for a new durable pump under development (IFP), and a commercially available pump (Medtronic 722G, M722G).

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 08,2022

BD, Direct Relief and National Association of Community Health Centers Advance Health Equity in the U.S. with $1 Million Grant

BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (NACHC), today announced they have awarded four community health centers with a total of $1.08 million to implement programs to support chronic disease management to underserved communities.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES